| Dr Gianina Cazan-london, MD | |
|
1 Perkins Sq, Akron, OH 44308-1063 | |
| (330) 543-4500 | |
| (330) 543-4508 |
| Full Name | Dr Gianina Cazan-london |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 26 Years |
| Location | 1 Perkins Sq, Akron, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407834351 | NPI | - | NPPES |
| OB56025 | Other | MI | BCBSM AND MEDICARE GROUP PIN |
| 1417961137 | Other | MI | BCBS - BRONSON |
| 1407834351 | Medicaid | MI |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mclaren Greater Lansing | 7214833466 | 104 |
News Archive
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
New figures from the federal government shows that the prevalence of obesity in the U.S. largely leveled off over the last decade, even as some individual groups, such as boys from ages 6 to 19, saw increases.
The coronavirus disease 2019 (COVID-19) pandemic has already caused over 117.6 million confirmed cases the world over. Yet, researchers debate the exact incidence of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19's causative pathogen.
› Verified 2 days ago
| Entity Name | Mclaren Greater Lansing |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265600902 PECOS PAC ID: 7214833466 Enrollment ID: O20031217000526 |
News Archive
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
New figures from the federal government shows that the prevalence of obesity in the U.S. largely leveled off over the last decade, even as some individual groups, such as boys from ages 6 to 19, saw increases.
The coronavirus disease 2019 (COVID-19) pandemic has already caused over 117.6 million confirmed cases the world over. Yet, researchers debate the exact incidence of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19's causative pathogen.
› Verified 2 days ago
| Entity Name | Edward W Sparrow Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831139088 PECOS PAC ID: 6709799166 Enrollment ID: O20040102000790 |
News Archive
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
New figures from the federal government shows that the prevalence of obesity in the U.S. largely leveled off over the last decade, even as some individual groups, such as boys from ages 6 to 19, saw increases.
The coronavirus disease 2019 (COVID-19) pandemic has already caused over 117.6 million confirmed cases the world over. Yet, researchers debate the exact incidence of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19's causative pathogen.
› Verified 2 days ago
| Entity Name | Mclaren Flint |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275807372 PECOS PAC ID: 8628975497 Enrollment ID: O20120620000454 |
News Archive
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
New figures from the federal government shows that the prevalence of obesity in the U.S. largely leveled off over the last decade, even as some individual groups, such as boys from ages 6 to 19, saw increases.
The coronavirus disease 2019 (COVID-19) pandemic has already caused over 117.6 million confirmed cases the world over. Yet, researchers debate the exact incidence of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19's causative pathogen.
› Verified 2 days ago
| Entity Name | Mclaren Greater Lansing |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972878452 PECOS PAC ID: 7214833466 Enrollment ID: O20121226000286 |
News Archive
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
New figures from the federal government shows that the prevalence of obesity in the U.S. largely leveled off over the last decade, even as some individual groups, such as boys from ages 6 to 19, saw increases.
The coronavirus disease 2019 (COVID-19) pandemic has already caused over 117.6 million confirmed cases the world over. Yet, researchers debate the exact incidence of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19's causative pathogen.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gianina Cazan-london, MD 1 Perkins Sq, Akron, OH 44308-1063 Ph: (330) 543-4500 | Dr Gianina Cazan-london, MD 1 Perkins Sq, Akron, OH 44308-1063 Ph: (330) 543-4500 |
News Archive
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.
A study led by Xiaoching Li, PhD, at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence, has shown for the first time how two tiny molecules regulate a gene implicated in speech and language impairments as well as autism disorders, and that social context of vocal behavior governs their function.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
New figures from the federal government shows that the prevalence of obesity in the U.S. largely leveled off over the last decade, even as some individual groups, such as boys from ages 6 to 19, saw increases.
The coronavirus disease 2019 (COVID-19) pandemic has already caused over 117.6 million confirmed cases the world over. Yet, researchers debate the exact incidence of reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19's causative pathogen.
› Verified 2 days ago
Dr. Amy M Burkett, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Park West Blvd, Akron, OH 44320 Phone: 330-869-9777 Fax: 330-869-0052 | |
David M Nash, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 95 Arch St, Ste 250, Akron, OH 44304 Phone: 330-375-7722 Fax: 330-253-6708 | |
Cecilia A. Ellis, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 605 N Cleveland Massillon Rd, Akron, OH 44333 Phone: 330-668-6545 Fax: 330-668-2726 | |
James Graham, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 919 E Turkeyfoot Lake Rd Ste A, Akron, OH 44312 Phone: 330-899-9626 Fax: 330-633-6068 | |
John A. Black, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1622 E Turkeyfoot Lake Rd, #301, Akron, OH 44312 Phone: 330-344-8565 Fax: 330-896-7085 | |
Dr. Muriel Tabet, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Park West Blvd, Ste 200, Akron, OH 44320 Phone: 330-869-9777 Fax: 330-865-6011 | |
L Ann Nunnally, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 839 E Market St, Akron, OH 44305 Phone: 330-535-9191 |